Erythropoietin’s inhibiting impact on hepcidin expression occurs indirectly

Elena Gammella,1 Victor Diaz,2 Stefania Recalcati,1 Paolo Buratti,1 Michele Samaja,3 Soumyadeep Dey,4 Constance Tom Noguchi,4 Max Gassmann,2,5 and Gaetano Cairo1

1Department of Biomedical Sciences for Health, University of Milano, Milan, Italy; 2Institute of Veterinary Physiology, Vetsuisse Faculty, and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland; 3Department of Health Science, University of Milano, Milan, Italy; 4Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; and 5Universidad Peruana Cayetano Heredia, Lima, Peru

Submitted 29 September 2014; accepted in final form 11 December 2014

Gammella E, Diaz V, Recalcati S, Buratti P, Samaja M, Dey S, Noguchi CT, Gassmann M, Cairo G. Erythropoietin’s inhibiting impact on hepcidin expression occurs indirectly. Am J Physiol Regul Integr Comp Physiol 308: R330–R335, 2015. First published December 17, 2014; doi:10.1152/ajpregu.00410.2014.—Under conditions of accelerated erythropoiesis, elevated erythropoietin (Epo) levels are associated with inhibition of hepcidin synthesis, a response that ultimately increases iron availability to meet the enhanced iron needs of erythroid lineage cells. In the search for erythroid regulators of hepcidin, many candidates have been proposed, including Epo itself. We aimed to test whether direct interaction between Epo and the liver is required to regulate hepcidin. We found that prolonged administration of high doses of Epo in mice leads to great inhibition of liver hepcidin mRNA levels, and concomitant induction of the hepcidin inhibitor erythroferrone (ERFE). Epo treatment also resulted in liver iron mobilization, mediated by increased ferroportin activity and accompanied by reduced ferritin levels and increased TfR1 expression. The same inhibitory effect was observed in mice that do not express the homodimeric Epo receptor (EpoR) in liver cells because EpoR expression is restricted to erythroid cells. Similarly, liver signaling pathways involved in hepcidin regulation were not influenced by the presence or absence of hepatic EpoR. Moreover, Epo analogs, possibly interacting with the postulated heterodimeric β common EpoR, did not affect hepcidin expression. These findings were supported by the lack of inhibition on hepcidin found in hepatoma cells exposed to various concentrations of Epo for different periods of times. Our results demonstrate that hepcidin suppression does not require the direct binding of Epo to its liver receptors and rather suggest that the role of Epo is to stimulate the synthesis of the erythroid regulator ERFE in erythroblasts, which ultimately down-regulates hepcidin. 

Address for reprint requests and other correspondence: G. Cairo, Dept. of Biomedical Sciences for Health, Univ. of Milano, Milan, Italy (e-mail: gaetano.cairo@unimi.it).

MATERIALS AND METHODS

Animals. Mice were maintained under standard conditions with free access to water and food (170 mg iron/kg) in compliance with the “Principles of Laboratory Animal Care,” as described previously (3). We used 6- to 8-wk-old male ICR CD1 and C57BL/6 wild-type mice, as well as TgEpoR mice (TgEPOR), with EpoR expression restricted to hematopoietic tissue (erythroid GATA-1 promoter/EpoR cDNA transgene) established on the EpoR−/− background (18). Genotypes...
were identified by PCR. Mice were injected with saline, or different amounts of Epo (epoetin alpha, Eprex; Janssen-Cilag) appropriately diluted in saline. Mice were also treated with the Epo-like peptide ARA290 that consists of 11 amino acids or with carbamylated Epo (CEpo) diluted about 1,000 fold in saline from 1.8 and 1.6 mg/ml stock solutions, respectively. Livers and spleens were harvested, frozen in liquid nitrogen, and stored at −80°C. All procedures were approved by the corresponding authorities and followed institutional guidelines of the University of Milano and the National Institute of Diabetes and Digestive and Kidney Diseases Animal Care and Use Committee.

Cell cultures. Human HepG2 and mouse c1c7 hepatoma cell lines obtained from the American Type Culture Collection were cultured in DMEM medium, 10% FBS, 0.5 units/ml penicillin/streptomycin, and 1 mM L-glutamine at 37°C and 5% CO2 and exposed to various concentrations of Epo for different periods of time at a cell density of 1 × 10^4 cells/cm².

Blood analyses. Hematocrit of heparinized blood was measured in duplicate by using a microcentrifuge.

RNA analysis. Hepcidin, BMP6, and ERFE mRNA levels were measured by quantitative RT-PCR, as previously described (3). Total RNA isolated from liver and spleen using TRI reagent (Sigma), and the obtained cDNA served as a template for RT-PCR, based on the TaqMan methodology (Life Technologies). Primers: mouse hepcidin: Mm00519025_m1; mouse BMP6 Mm01332882_m1; mouse 18S RNA Mm03928990_g1; mouse ERFE Mm00557748_m1; human hepcidin Hs00221783_m1; and human 18S RNA Hs03928985_g1 (Applied Biosystems). Thermal cycling parameters were 40 cycles at 95°C for 15 s and 60°C for 1 min. Samples were analyzed in triplicate and normalized to the housekeeping gene 18S RNA.

Protein analysis. Tissue lysates were prepared in RIPA buffer, incubated on ice for 30 min, and centrifuged at 13,600 g for 5 min. Proteins in the supernatant were separated on SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Amersham Biosciences).
Membranes were processed and incubated with primary antibodies (Ferroportin, Novus Biologicals NBP1-21502, 1:1,500; TfR1 Invitrogen 136800, 1:500; ERK1/2 Cell Signaling no. 9102, 1:1,000; phospho ERK1/2 Cell Signaling no. 9101, 1:1,000; Jak2 Cell Signaling no. 3230, 1:1,000; Phospho Jak2 Cell Signaling no. 3776, 1:1,000; β-actin Cell Signaling no. 5125, 1:5,000) and HRP-conjugated secondary antibodies. The antigens were detected using an immunodetection kit (ECL Basic, Amersham Biosciences). Each sample was loaded on 2–4 different gels, and the results were quantified using ImageJ software (v1.45q, National Institutes of Health). Background control was not applied, and the sum of all peak heights was used for quantification (5). Data were normalized to β-actin and to wild-type (Wt) controls.

Statistical analysis. Data are presented as means ± SE. Differences were analyzed using the Mann-Whitney U-test for unpaired samples. For those experiments involving three or more groups, the Mann-Whitney U-test was performed if prior Kruskal-Wallis analysis of variance revealed an effect of the treatment. All of the data were analyzed using SPSS 19.0 (SPSS Worldwide), and significance level was set to \( P < 0.05 \).

RESULTS AND DISCUSSION

As it has been shown that Epo administration to hepatic cells in vitro resulted in a 50% inhibition of hepcidin mRNA expression (4, 14), we decided to reinvestigate hepcidin expression in HepG2 cells exposed to varying Epo concentrations for two different time periods. The results reported in Fig. 1A show that in cells exposed to increasing concentrations of Epo for 24 h, hepcidin mRNA levels were not significantly changed; comparable results were obtained after 3 h of treat-
Erythropoietin does not inhibit hepcidin directly

Fig. 3. A: data were obtained from ICR CD1 and C57BL/6 wild-type mice (without differences in response between strains). Mice were treated for four consecutive days with saline (WT; n = 4) or 2,000 IU/kg daily Epo (Epo; n = 4), 4 h with 1,200 IU/kg of Epo (Epo; n = 5). Moreover, wild-type (WT) controls and TgEpoR mice (TgEpoR) with EpoR expression restricted to hematopoietic tissue (n = 5) were treated for 10 consecutive days with saline or 1,200 IU/kg daily Epo. Erythroferrone (ERFE) expression was measured by RT-PCR. Samples were analyzed in triplicate and normalized to the housekeeping gene 18S RNA. Dots and solid black line represent single animals and the mean, respectively. For better visualization, the y-axis scale has been set up using a logarithmic scale. Data are presented as means ± SE. *P < 0.05; **P < 0.01.

B: data were obtained from WT mice treated for 10 consecutive days with saline (Ctrl; n = 4) or 10 μg/kg CEPo daily (CEpo; n = 4); mice treated for four consecutive days with a control peptide (Ctrl; n = 4); mice 24 h or 4 days after injection of 3 or 12 μg/kg daily of ARA290 (n = 3 for each group). Hepcidin (HAMP) expression was measured by RT-PCR. Samples were analyzed in triplicate and normalized to the housekeeping gene 18S RNA. Dots and solid black line represent single animals and the mean, respectively. For better visualization, y-axis scale has been set up using a logarithmic scale. Data are presented as means ± SE. *P < 0.05; **P < 0.01.
a nearly 100-fold stimulation of ERFE expression in both Wt and TgEpoR mice (Fig. 3A). These results further suggest that the role of Epo is to stimulate the synthesis of the erythroid regulator ERFE, which, in turn, inhibits hepcidin.

These findings clearly indicated that liver EpoR is not involved in hepcidin suppression; however, it cannot be formally excluded that in both Wt and TgEpoR mice, the inhibitory effect on hepcidin exerted by high doses of exogenous Epo was not mediated by its interaction on hepatocytes with its classical homodimeric receptor, but with the heterodimeric β common receptor (βcR), which has been proposed to mediate Epo’s tissue-protective activity (9). This possibility is further supported by the suggestion that the affinity of βcR is much lower (1–20 nmol/l) than that of the classical receptor (100–200 pmol/l), and thus, the interaction with the heterodimeric receptor becomes active only upon application of high-Epo dosage (1). To address this issue, we treated the animals with CEpo, a compound thought to interact solely with the βcR, as shown by its inability to stimulate erythropoiesis (9) (Fig. 3B).

In line with a study that used different treatment schedules (15), we did not observe significant down-modulation of hepcidin expression in animals treated for 10 days with doses of CEpo that were similar to those used for Epo and were shown to be tissue-protective (9). As expected, hematocrit was unchanged (Fig. 1C). Similarly ineffective in downregulating hepcidin (Fig. 3B) and increasing hematocrit (Fig. 1C) were our treatments for 1 or 4 days with two different doses of ARA290, a peptide that binds the β common receptor and shows the same protective properties of CEpo (19).

In summary, the present results showed that Epo does not directly down-modulate hepcidin expression. While this manuscript was in preparation, ERFE, a new hormone that inhibits hepcidin expression during stress erythropoiesis in mice, was characterized and published (7). In line with that study, our results (see Figs. 1B and 3A) support the idea that under conditions of markedly increased erythroid activity, Epo stimulates the synthesis of the regulator ERFE, which ultimately downregulates hepcidin. In fact, using mice with EpoR restriction directed to hematopoietic cells only, we demonstrated that hepcidin suppression does not require the binding of Epo to its receptor on the surface of hepatocytes. Moreover, administration of Epo analogs, possibly interacting with the postulated βcR, which is thought to mediate the tissue-protecting activity of Epo (1, 9), did not affect hepcidin expression either. In conclusion, our findings demonstrating that hepcidin suppression does not require the direct binding of Epo to its homodimeric or heterodimeric receptor on the surface of hepatocytes were supported by the unaffected hepcidin expression found in human and mouse hepatoma cells exposed to Epo.

Perspectives and Significance

Our data indicate that the effect of Epo on the liver’s expression of hepcidin is not directly mediated by its interaction with high or low affinity EpoR on hepatocytes, but rather suggest that the role of Epo is to stimulate the production of the erythroid regulator ERFE in erythropoietically active tissue, which ultimately inhibits hepcidin expression.

ACKNOWLEDGMENTS

We thank M. Brines for kindly providing CEpo, and S. Pankratova for her kind gift of ARA290.

GRANTS

This study was supported by grants from Ministero Istruzione, Universita e Ricerca (PRIN Project) and World Anti-Doping Agency to G. Cairo, and from the Zurich Center for Integrative Human Physiology, the Swiss National Science Foundation to M. Gassmann.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS


REFERENCES


AJP-Regul Integr Comp Physiol  doi:10.1152/ajpregu.00410.2014 • www.ajpregu.org

Downloaded from http://ajpregu.physiology.org/ on 2017-04-18

by 10.220.32.246 on April 19, 2017

https://doi.org/10.1152/ajpregu.00410.2014

R334


